Gilead Sciences Inc. (GILD)

NASDAQ: GILD · USD

—

Dự phòng tiếng AnhVI

Hiển thị bản gốc tiếng Anh trong khi đang dịch

Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

StockMarketAgent Research · Analyzed 2026-09-09

Our latest published analysis: GILD rated Hold

Gilead Sciences Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$140 / share

Potential value

$273 / share

Upside to FV

-4.8%

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$187.2B
P/E (forward)	15.4x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 15.4x
Market cap: $187.2B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$27.31B	$27.28B	$27.12B	$28.75B	$29.44B	+1.9%
Gross profit	$20.70B	$21.62B	$27.12B	$22.50B	$23.21B	+2.9%
Operating income	$9.92B	$7.33B	$7.61B	$1.66B	$10.02B	+0.3%
Net income	$6.23B	$4.59B	$5.67B	$480.0M	$8.51B	+8.1%
EPS (diluted)	$4.93	$3.64	$4.50	$0.38	$6.78	+8.3%
EBITDA	$11.33B	$8.85B	$7.61B	$4.43B	$13.58B	+4.6%
R&D	$4.60B	$4.98B	$5.72B	$5.91B	$5.80B	+6.0%
SG&A	$5.25B	$5.67B	$6.09B	$6.09B	$5.77B	+2.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	—	—	—	—	—	—	Bán
ABT	Abbott Laboratories	—	—	—	—	—	—	Giảm
ACN	Accenture plc	—	—	—	—	—	—	Giữ
ALGN	Align Technology Inc.	—	—	—	—	—	—	Giảm
ALNY	Alnylam Pharmaceuticals, Inc.	—	—	—	—	—	—	Mua mạnh
AMGN	Amgen Inc.	—	—	—	—	—	—	Mua

Base and Bull scenarios

Base60%

Price target

$139.59

-4.8% from spot

FY2027 analyst consensus estimates support higher revenue and adjusted earnings. Growth then slows because HIV concentration limits the evidence for a longer expansion.

FY2027 revenue and adjusted EPS meet analyst consensus estimates.
Growth fades after FY2027 rather than continuing to accelerate.

Bull20%

Price target

$273.40

+86.4% from spot

Improvement beyond FY2027 requires a larger non-HIV contribution and strong free cash flow. These are scenario conditions, while the cited evidence records FY2025 levels. Lower cell-therapy sales or weaker free cash flow would disconfirm this path.

A larger non-HIV contribution is required; FY2025 cell-therapy sales establish a starting level, not future growth.
Free cash flow would need to remain strong relative to the FY2025 reported level.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($139.59). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
4.9%	$166	$180	$199	$228	$276
5.9%	$143	$151	$160	$174	$192
6.9%	$128	$133	$140	$146	$155
7.9%	$117	$120	$124	$129	$134
8.9%	$109	$111	$114	$117	$121

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Forward P/E15.4

P25 n/aP50 n/aP75 n/a

Trailing P/E18.4

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

Deeper analysis on GILD

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this GILD report

What is the latest published GILD stock rating?

Gilead Sciences Inc. is shown with Hold in the latest published report, analyzed 2026-09-09. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GILD analysis?

The full latest published report, analyzed 2026-09-09, lives at /stocks/GILD/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for GILD?

The latest published report analyzed 2026-09-09 gives GILD a fair value of USD 140 and a potential value of USD 273. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the GILD page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-09). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldGILD · Fair value $140-4.8%

Read full analysis →

Category	Score	Reading
Valuation	4.5
Management	6.5
Balance Sheet	3.5
Profitability	1.5
Revenue Growth	6.0
Risk Assessment	5.0
Competitive Moat	1.0
Earnings Quality	7.5
Capital Efficiency	7.5

Gilead Sciences Inc. (GILD)

Our latest published analysis: GILD rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · GILD

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on GILD

Frequently asked questions

Lịch sử xếp hạng